HOME > EVIDENCE
HOME > EVIDENCE
Evidence that precision at the electrode translates into clinical value
Evidence that precision at the electrode translates into clinical value
Aleva's platform is backed by peer-reviewed publications and post-market clinical data, providing a validated foundation for partner-led development.
Aleva's platform is backed by peer-reviewed publications and post-market clinical data, providing a validated foundation for partner-led development.
Aleva's platform is backed by peer-reviewed publications and post-market clinical data, providing a validated foundation for partner-led development.
Early proof of directional benefit
Early proof of directional benefit
Aleva's 2014 Brain publication provided foundational clinical proof that directional stimulation can improve therapy delivery in humans. In the intraoperative pilot study, the best directional configuration widened the therapeutic window by 41.3% compared with omnidirectional stimulation and reduced the current needed for beneficial effects by 43%.
Real-world clinical evidence
Real-world clinical evidence
Real-world clinical evidence
48%
Symptom improvement, Stim ON /
Med OFF (UPDRS III)
Symptom improvement, Stim ON /
Med OFF (UPDRS III)
Symptom improvement, Stim ON /
Med OFF (UPDRS III)
63%
Reduction in medication
at 6 months (LEDD)
Reduction in medication
at 6 months (LEDD)
Reduction in medication
at 6 months (LEDD)
65%
Patients using directional
stimulation 6 months
Patients using directional
stimulation 6 months
Patients using directional
stimulation 6 months
Post-market clinical follow-up across major Movement Disorder centres in Germany tracked outcomes at 3 and 6 months, showing symptom improvement, reduced medication burden and sustained use of directional stimulation.
Post-market clinical follow-up across major Movement Disorder centres in Germany tracked outcomes at 3 and 6 months, showing symptom improvement, reduced medication burden and sustained use of directional stimulation.
Post-market clinical follow-up across major Movement Disorder centres in Germany tracked outcomes at 3 and 6 months, showing symptom improvement, reduced medication burden and sustained use of directional stimulation.
PMCF data from post-market clinical follow-up in Germany. Not yet published. Data available under NDA on request.
PMCF data from post-market clinical follow-up in Germany. Not yet published. Data available under NDA on request.
Additional published work strengthens the evidence base
Additional published work strengthens the evidence base
Additional published work strengthens the evidence base
Beyond the landmark 2014 Brain study and post-market follow-up, Aleva-related publications have explored how directional stimulation shapes activated tissue volume, how stimulation sweet spots can be modelled to predict clinical outcomes, and how directional local field potentials may inform future closed-loop programming.
Beyond the landmark 2014 Brain study and post-market follow-up, Aleva-related publications have explored how directional stimulation shapes activated tissue volume, how stimulation sweet spots can be modelled to predict clinical outcomes, and how directional local field potentials may inform future closed-loop programming.
Beyond the landmark 2014 Brain study and post-market follow-up, Aleva-related publications have explored how directional stimulation shapes activated tissue volume, how stimulation sweet spots can be modelled to predict clinical outcomes, and how directional local field potentials may inform future closed-loop programming.
What this evidence means for a licensing partner
What this evidence means for a licensing partner
What this evidence means for a licensing partner
Why this matters to partners
Why this matters to partners
Why this matters to partners
Licensing Aleva's platform means inheriting a validated evidence base, not starting from scratch. Peer-reviewed publication, documented human use, and post-market follow-up data give partners a more credible foundation for indication strategy, product positioning, and clinical development planning.
Licensing Aleva's platform means inheriting a validated evidence base, not starting from scratch. Peer-reviewed publication, documented human use, and post-market follow-up data give partners a more credible foundation for indication strategy, product positioning, and clinical development planning.